Questions about Akebia's disclosure of liver toxicity in a trial raise a red flag over vadadustat, the company's experimental anaemia treatment.
With few pipeline catalysts this year the pressure is growing on Lundbeck's new chief executive, Deborah Dunsire, to deliver a deal. But the company only has $5bn to…
Johnson & Johnson's esketamine should get approved in depression, but a safety plan requiring supervision raises questions about its commercial promise.
Others in the FDA queue include Bausch’s psoriasis therapy Duobrii and Motif Bio’s antibiotic Iclaprim.
In a constrained pricing environment a volume play could help sales of Lilly's Emgality as it takes on Amgen’s Aimovig and Teva’s Ajovy.
A dissection of five years' biopharma buyout spending reveals that most deals are struck over preclinical and mid-stage assets, while buyers remain most interested…
As one headache for Acadia eases another begins, with unconvincing results from a mid-stage depression trial of Nuplazid.
Limiting abuse and reducing risks are the differentiating factors for projects from Kempharm and Supernus.
Japanese group prefers M&A over license